Navigation Links
Amgen To Webcast 2013 Business Review Meeting On February 7
Date:1/31/2013

THOUSAND OAKS, Calif., Jan. 31, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will hold its Business Review Meeting on Thursday, Feb. 7, 2013, at the Mandarin Oriental Hotel, 80 Columbus Circle, New York City, beginning at 8 a.m. Eastern Standard Time. In the meeting, Robert A. Bradway , chairman and chief executive officer, Sean E. Harper , M.D., executive vice president, Research and Development, Anthony C. Hooper , executive vice president, Global Commercial Operations, and Jonathan M. Peacock , executive vice president and chief financial officer, will discuss the Company's plans to manage our diversified portfolio of in-market products, a strong emerging pipeline, and other initiatives that will drive future growth.

The webcast will be available to members of the news media, investors and the general public, and is expected to last approximately four hours.

The webcast of the meeting, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay at least 30 days after the event.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have change
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today it has completed enrollment of the ... Committee (DRC) earlier this year, into the company,s ... first-in-class innate defense regulator (IDR) and is being ...
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
... , HELSINKI, Dec. 14 Cancer ... with the introduction of RapidArc® radiotherapy technology from Varian Medical ... radiotherapy clinic in the Nordic region. Clinicians at Docrates Clinic ... radiotherapy to treat patients with multiple brain metastases and cancers ...
... , WALTHAM, Mass., Dec. ... authority on medical technology market intelligence, increased use of safety ... be a key driver of the enteral feeding device markets ... and European Markets for Enteral Feeding Devices 2010 report ...
Cached Medicine Technology:Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3
(Date:8/31/2015)... ... August 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics proudly announces that ... Influence by Modern Luxury’s The Atlantan Magazine. , This award for the ... King. Her idea and vision to bring to Atlanta a true luxury experience ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... When it comes to undergoing a hair ... top of the head. Adding more volume to the hair on top of the ... patients who have a good amount of donor hair on other areas of their head. ...
(Date:8/31/2015)... ... August 31, 2015 , ... Women’s Excellence in Wellness, ... to the Lake Orion area. This program is one of the most successful ... management program will incorporate group fitness and nutritional consultations to help people lose ...
(Date:8/31/2015)... ... ... Coast Dental Vista is celebrating its recent grand opening with ... near Albertsons in the Foothill Center, located at 1279 E. Vista Way. There will ... Lopp. Call (760) 208-2518 for more details or stop by on September 5. , ...
(Date:8/31/2015)... Scotch Plains, NJ (PRWEB) , ... August 31, ... ... in practice! Garden State Urology was formed in 2008, the result of a ... on the principle that by working cooperatively, they could provide more cost-effective and ...
Breaking Medicine News(10 mins):Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3Health News:NJ Top Docs Presents, Garden State Urology! 2
... campaign,with ,Better Fats Sisters, DALLAS, July 24 ... (monounsaturated and polyunsaturated) can help,reduce their risk of heart ... Association., "Heart disease remains the No. 1 killer ... fats lately and what not to eat. That,s why,it,s ...
... with disabilities means more who can keep working, reduces load on ,Social ... ... With the signing of the Americans with Disabilities Act on July 26, ... and their families. In 18 years, thousands of people have gained better ...
... Key Highlights, Misys plc (LSE: MSY) delivers ... the next phase of the turnaround. Misys generated Group,revenues(1) ... GBP81m,37% ahead of last year. Misys is executing on ... turnaround plan, building a platform for growth., To ...
... study out of Wake Forest University Baptist Medical Center ... are having a heart attack, even when laboratory tests ... from a registry called i*trACS, and analyzed patients with ... (EDs) in eight participating U.S. centers. , The ...
... and Naturalization ready at Passport ... ... vaccine requirements will affect,anyone who is applying for an immigrant visa ... permanent residence. Applicants,must show proof of vaccinations against vaccine-preventable diseases, as,recommended ...
... varicose veins in scrotum boosts sperm count, motility, study ... simple, minimally invasive procedure can treat a common cause ... having a baby, a new study finds. , The ... vessels in the scrotum which prevents the normal circulation ...
Cached Medicine News:Health News:Most Americans Don't Know 'Better Fats' Benefit Heart Health 2Health News:Most Americans Don't Know 'Better Fats' Benefit Heart Health 3Health News:Allsup Salutes 18th Anniversary of Americans with Disabilities Act 2Health News:Allsup Salutes 18th Anniversary of Americans with Disabilities Act 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 2Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 4Health News:Study shows emergency physicians have good first instincts in diagnosing heart attacks 2Health News:USCIS Tightens Vaccination Requirements 2Health News:Simple Procedure Improves Male Fertility 2Health News:Simple Procedure Improves Male Fertility 3
... Splint is constructed of a durable heat moldable ... flexor tendons of the hand and fingers from ... in the later stages of the healing process. ... hand and positions the wrist at 30° of ...
Bunell Mini-Modified Safety Finger Pin reduces PIP flexion contractures....
... FoamWrap Finger Trappers are ideal for ... restore finger motion. Finger Trappers' non-slip foam ... place the fingers in traction. These are ... size. Sold in packages of 5 and ...
... physiological causes of minor knee pain like ... in concert with the motion of the ... and patellar tendon and assisting in the ... plastic support with high density foam padding ...
Medicine Products: